ライフサイエンスコーパス: FFP

1 FFP transfusion has limited efficacy and is associated w

2 FFP transfusions were independently associated with an i

3 FFP was defined as a PSA rise <= 0.2ng/mL above nadir po

4 FFP was defined as a PSA rise of no more than 0.2 ng/mL

5 FFP was significantly superior among patients with a pro

6 FFP-based phylogenetic trees of seven gastric Helicobact

7 ifference, 0.001 [95% CI, -0.004 to 0.005]), FFP score (mean [SD], 0.017 [1.004] vs 0.007 [0.958]; ad

8 54% v 47%, P = .25; EFS: 53% v 27%, P < .01; FFP: 62% v 32%, P < .01).

9 1; 95% confidence interval (CI), 1.89-3.09], FFP (AOR = 2.81; 95% CI, 2.02-3.91), and platelets (AOR

10 hage, consideration should be given to 1 : 1 FFP :PRBC transfusion, and in severe cases, rFVIIa.

11 s and divided into two groups: high (RBCs>20/FFP>5) or low (RBCs<20/FFP<5) amount of blood products.

12 groups: high (RBCs>20/FFP>5) or low (RBCs<20/FFP<5) amount of blood products.

13 nd 28 to PCC) and 50 received study drug (23 FFP and 27 PCC).

14 d with fresh frozen plasma (FFP) or with 50% FFP and 50% albumin.

15 eiving RBCs (AOR = 0.45; 95% CI, 0.35-0.57), FFP (AOR = 0.37; 95% CI, 0.27-0.51), and platelets (AOR

16 comparative 5-year results are 82% and 62% (FFP), 78% and 58% (EFS), and 89% and 79% (OS), respectiv

17 ts with none of these factors enjoyed an 85% FFP at 4 years compared with 41% for patients with one o

18 nment identified one of the potentials as an FFP.

19 tes in infarcts; entrainment demonstrated an FFP at 66 (86%) sites.

20 als, measuring the postpacing interval to an FFP would lead to erroneous classification of the site l

21 were found for RBCs per operation, FFP, and FFP per operation (p<.05).

22 primary outcome was the difference in FI and FFP scores from the 2015 baseline assessment to the 2016

23 st case fatality in reversal of VKA-ICH, and FFP may be equivalent to PCC.

24 titrypsin, and antiplasmin-in S/D plasma and FFP.

25 Mean number of PRBCs and FFP transfused were 7.7 +/- 12 U, 6 U, and 5 +/- 12 U, r

26 nt (n = 250) of them received both PRBCs and FFP.

27 f 16S rRNA genes and ribosomal proteins, and FFP- and core genome single nucleotide polymorphism-base

28 tors for overall and event-free survival and FFP.

29 FFP ratio with those who did not receive any FFP.

30 nd not altered during pacing were defined as FFP.

31 a suggest that it may not be as effective as FFP for the treatment of bleeding in patients with syste

32 Six serious adverse events were judged to be FFP related (four cases of haematoma expansion, one anap

33 FFP, and BES; the FFP:RBC, BES:RBC, and BES: FFP ratios were given in the OR.

34 orrelation with OR FFP: RBC, BES:RBC, or BES:FFP ratios and phase 2 hypoproteinemia or weight gain.

35 VPP/EVA hybrid produces significantly better FFP, EFS, and OS than VAPEC-B in patients with previousl

36 ed PLT (6.7%; P = 0.009 vs. SOC), and 3 both FFP and PLT (not significant).

37 ived FFP, 10 (33.3%) PLT, and 4 (13.3%) both FFP and PLT.

38 sex, diagnosis, and transplant center, both FFP and SPPB were associated with increased risk of deli

39 The IPS was prognostic for both FFP (P < .001) and OS (P < .001), with 5-year FFP rangin

40 In both FFP trees, the basal group of the E. coli/Shigella phylo

41 , p = 0.041), compared to reversal with both FFP and PCC (27.8%, reference).

42 [CI] = 1.784-3.616, p < 0.001), followed by FFP alone (45.6%, HR = 1.344, 95% CI = 0.934-1.934, p =

43 ompleted SPPB assessments; 28% were frail by FFP (95% confidence interval [CI], 24-33%) and 10% based

44 811 participants [13.7%] considered frail by FFP score), SPPB scores (mean [SD], 6.91 [3.34] vs 7.21

45 of PCT-FFP compared with conventional FFP (C-FFP).

46 on, were transfused with either PCT-FFP or C-FFP for up to 7 days.

47 light chain fluorescent fusion protein (CLC-FFP), suggesting that DRP1C may participate in clathrin-

48 Of 395 subjects, 354 completed FFP assessments and 262 completed SPPB assessments; 28%

49 significantly lower use of blood components (FFP, PLTs, and cryoprecipitate) in the TEG group compare

50 se experiments demonstrate that convalescent FFP shows promise as a postexposure HPS prophylactic.

51 uired coagulopathy similarly to conventional FFP.

52 safety of PCT-FFP compared with conventional FFP (C-FFP).

53 he 95% confidence intervals for CR duration, FFP, and OS differences at 5 years were -8% to 15%, -8%

54 se therapy by all outcome measures (OS, EFS, FFP).

55 with stable disease, continue to experience FFP 20+ to 50+ months after study entry.

56 tients (22%; 95% CI, 13% to 46%) experienced FFP for two cycles, and eight patients remained free fro

57 oplastin time (PTT) in response to the first FFP transfusion.

58 plasma FV levels peaked by 2 hours following FFP administration and were undetectable 96 hours later.

59 blood component usage, and safety following FFP transfusions for up to 7 days.

60 ard ratios were 1.30 (95% CI, 1.01-1.67) for FFP and 1.53 (95% CI, 1.19-1.59) for SPPB.

61 n, correction in the PT and PTT adjusted for FFP dose and patient weight was not different.

62 The criteria for FFP were then assessed in a second cohort of five patien

63 he total number of possible words needed for FFP-k can range from 4(6)=4096 to 4(15).

64 restaging Ga scans were more predictive for FFP than final restaging Ga scans because patients who r

65 for the recommended optimal "resolution" for FFP.

66 Mean INR and platelet triggers for FFP and platelet transfusions were 1.9 +/- 1.3 and 60000

67 100 g FFP contributes fairly about 5 (Fe) to 10% (Mn, Ca & Mg)

68 High FFP:RBC transfusion ratios are applied mostly to patient

69 ly different in patients who received a high FFP:RBC ratio compared with those who received a low rat

70 ined to the prostatic fossa demonstrate high FFP, despite receiving less extensive radiotherapy and l

71 fined to the prostate fossa demonstrate high FFP, despite receiving less extensive radiotherapy and l

72 surgery, the aOR for death favored the high FFP:RBC ratio subgroup (aOR, 0.16; 95% CI, 0.03-0.79; P

73 for 30-day mortality when comparing the high FFP:RBC ratio vs the low FFP:RBC ratio subgroups (aOR, 1

74 Compared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity.

75 There were no differences in FFP.

76 ation and lack inhibitory activity, while in FFP only the active conformation is present.

77 th the membrane-associated Ca(2+) indicator, FFP-18, it is shown that store-operated Ca(2+) entry (SO

78 sealed envelopes to 20 mL/kg of intravenous FFP or 30 IU/kg of intravenous four-factor PCC within 1

79 Because the risk-benefit ratio of a liberal FFP or platelet transfusion strategy for critically ill

80 ted for evaluating a restrictive vs. liberal FFP or platelet transfusion strategy for nonbleeding pat

81 ed trials evaluating restrictive vs. liberal FFP transfusion strategies are warranted.

82 medicine, the aOR for death favored the low FFP:RBC ratio subgroup; general surgery: aOR, 4.27 (95%

83 comparing the high FFP:RBC ratio vs the low FFP:RBC ratio subgroups (aOR, 1.10; 95% CI, 0.72-1.70; P

84 The combination of FFP and PCC might be associated with the lowest case fat

85 Median dose of FFP was 17 mL/kg in patients who had INR corrected vs. 1

86 valuate the relative therapeutic efficacy of FFP and S/D plasma for the treatment of these diseases.

87 t simply a virally inactivated equivalent of FFP.

88 Examination of FFP:RBC transfusion ratios for patients without trauma.

89 ,000 neutralizing antibody units (NAU)/kg of FFP-protected hamsters from lethal disease when given up

90 OR); they received 14.2 RBC units, 854 mL of FFP, and 11.5 L of BES while in the OR.

91 We hypothesized that the practice of FFP transfusion in the medical intensive care unit is va

92 PSMA PET was highly predictive of FFP at 3 y after sRT.

93 n: PSMA PET results are highly predictive of FFP at 3 y in men undergoing sRT for BCR after RP.

94 PSMA was highly predictive of FFP at 3 years following sRT.

95 ion: PSMA PET result is highly predictive of FFP at 3 years in men undergoing sRT for BCR following R

96 on PSMA was more independently predictive of FFP than established clinical predictors, including PSA,

97 SMA PET was more independently predictive of FFP than established clinical predictors, including PSA,

98 after chemotherapy is strongly predictive of FFP with the Stanford V regimen despite the use of conso

99 The risk-benefit ratio of FFP transfusion in critically ill medical patients with

100 ars, transfusing 16569 U of RBCs, 13933 U of FFP, 5228 U of cryoprecipitate, and 22635 U of platelets

101 f crystalloid, 13 units of RBCs, 10 units of FFP, and 1 unit of platelets over 24 hours, with a mean

102 mmarized the current evidence for the use of FFP and platelet transfusions in critically ill patients

103 Furthermore, the use of FFP and platelets are associated with poorer perioperati

104 and management of a more restrictive use of FFP and platelets on surgical patients.

105 Early and aggressive use of FFP does not improve outcome after civilian injury.

106 In conclusion, the use of FFP phylogenetic clustering and in silico genotyping all

107 of LPs by 62%, without significant effect on FFP amplitude.

108 at were found to have a prognostic impact on FFP.

109 r results were found for RBCs per operation, FFP, and FFP per operation (p<.05).

110 ext, we test the robustness of the optimized FFP method at the nucleotide level, using a mutation mod

111 The optimum FFP method is applicable for comparing whole genomes or

112 There was no significant correlation with OR FFP: RBC, BES:RBC, or BES:FFP ratios and phase 2 hypopro

113 Our FFP trees are constructed with whole proteomes of 884 pr

114 ble similarities and differences between our FFP trees and those based on other methods in grouping a

115 e shown, our data favour the use of PCC over FFP in intracranial haemorrhage related to VKA.

116 Overall FFP and platelet transfusion rates were 8.9% and 3.8%, r

117 Overall, FFP was achieved in 64.5% (120/186) of those who receive

118 Overall, FFP was achieved in 64.5% (120/186) of those who receive

119 splantation, were transfused with either PCT-FFP or C-FFP for up to 7 days.

120 d to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP).

121 tivate pathogens in fresh frozen plasma (PCT-FFP).

122 These results suggest PCT-FFP supported hemostasis in the treatment of acquired co

123 (molecule-wall collisions) and liquid-phase FFP (molecule-molecule collisions) pyrolysis temperature

124 thus residence time) using the liquid-phase FFP method allows a tuning of reaction selectivities not

125 Since the solution-phase FFP method does not require the substrate to be volatile

126 ed frailty with the Fried Frailty Phenotype (FFP) and Short Physical Performance Battery (SPPB).

127 er frailty) and the Fried Frailty Phenotype (FFP) score (range, 0-5, with higher values indicating gr

128 Fresh-frozen plasma (FFP) and intermediate purity factor VIII concentrate wer

129 lood components such as fresh frozen plasma (FFP) and platelet transfusions are limited.

130 overall utilization of fresh frozen plasma (FFP) and platelets and the impact on perioperative outco

131 inical practice include fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC).

132 ify preprocedure use of fresh frozen plasma (FFP) and/or platelets (PLT).

133 ill, data on the use of fresh frozen plasma (FFP) are limited.

134 l antibody, obtained as fresh frozen plasma (FFP) from a HPS survivor.

135 early aggressive use of fresh frozen plasma (FFP) in a 1:1 ratio to packed red blood cells (PRBCs) ha

136 moved and replaced with fresh frozen plasma (FFP) or with 50% FFP and 50% albumin.

137 e the administration of fresh frozen plasma (FFP) prevents gastrointestinal bleeding in this individu

138 gh transfusion ratio of fresh frozen plasma (FFP) to red blood cells (RBCs) has spread to other surgi

139 safety and efficacy of fresh frozen plasma (FFP) versus prothrombin complex concentrate (PCC) in pat

140 blood cells (RBCs) and fresh frozen plasma (FFP) were recorded during hospital stay before the devel

141 ctivated alternative to fresh-frozen plasma (FFP).

142 ed blood cells [RBCs] + fresh frozen plasma [FFP] + platelets) had a median (interquartile range) fib

143 three blood components (fresh frozen plasma [FFP], PLTs, and cryoprecipitate) versus 87.2% in the SOC

144 ropose a simple improvement over the popular FFP method using only a typical word length of 3.

145 ent for distinguishing far-field potentials (FFP) due to depolarization of tissue at a distance from

146 compared with farmers' fertilizer practices (FFP), respectively.

147 e when comparing patients who had a 1:1 PRBC:FFP ratio with those who did not receive any FFP.

148 Patients were stratified by PRBC:FFP transfusion ratio over the first 24 hours.

149 to determine if early aggressive use of PRBC:FFP improved outcome.

150 ling for all significant variables, the PRBC:FFP ratio did not predict intensive care unit days, hosp

151 cted by using the feature frequency profile (FFP) method.

152 ar method, called feature frequency profile (FFP-k), finds the frequency distribution for all words o

153 ed by using the "feature frequency profile" (FFP) method of alignment-free comparison.

154 which feature (or l-mer) frequency profiles (FFP) of whole genomes are used for comparison-a variatio

155 is based on the feature frequency profiles (FFP), where the length of the feature (l-mer) is selecte

156 ted by comparing feature frequency profiles (FFPs) of whole proteomes.

157 analysis method feature frequency profiling (FFP) can be used to rapidly construct phylogenetic trees

158 nd predicts 5-year freedom from progression (FFP) and overall survival (OS) ranging from 42% to 84% a

159 Freedom from progression (FFP) and overall survival at 10 years were 83% and 79%,

160 urvival (EFS), and freedom from progression (FFP) at 4 years follow-up favored patients who received

161 nd points included freedom from progression (FFP) for > or= two cycles (one cycle = 28 days), objecti

162 PSMA PET for a 3-y freedom from progression (FFP) in men with BCR after RP undergoing salvage radioth

163 SMA PET for 3 year freedom from progression (FFP) in men with BCR post RP undergoing salvage radiothe

164 rvival was 48% and freedom from progression (FFP) was 62%.

165 up of 4 years, the freedom from progression (FFP) was 96% in postchemotherapy [(18)F]FDG-PET-negative

166 survival (OS) and freedom from progression (FFP) were 96% and 79%, respectively.

167 onths CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD + RT versus ABV

168 w-up of 4.9 years, freedom from progression (FFP), event-free survival (EFS), and overall survival (O

169 Freedom from progression (FFP), overall survival (OS), and freedom from second rel

170 aging Ga scans remain free from progression (FFP), whereas only 18% of patients who had positive earl

171 well-tolerated and associated with prolonged FFP in a small subset of patients with relapsed or refra

172 jor groups are observed between our proteome FFP tree and trees built with other methods; and (v) pre

173 jor groups, we present a simplified proteome FFP tree of monophyletic class or phylum with branch sup

174 In our whole-proteome FFP trees (i) Archaea, Bacteria, Eukaryota, and a random

175 for nine elements in their fresh fruit pulp (FFP) revealed genetic variability of 4.7-fold for K & Mg

176 igh-T/p liquid-phase "flash flow pyrolysis" (FFP) technique was applied to the thermolysis of Meldrum

177 spital variability in use of allogeneic RBC, FFP, and platelet transfusions in patients undergoing ma

178 is best predicted by shock time and the RBC, FFP, and BES infusions in the OR.

179 on pulse rate, arterial pH, shock time, RBC, FFP, and BES; the FFP:RBC, BES:RBC, and BES: FFP ratios

180 hock time had the best correlation with RBC, FFP, and BES administration in the OR as well as with ph

181 RBC:FFP transfusion ratios were calculated at 6 hours after

182 of platelets over 24 hours, with a mean RBC:FFP ratio of 1.58:1.

183 Resuscitation with a "low ratio" of RBC:FFP leads to earlier correction of coagulopathy, and ear

184 o" (RBC:FFP </= 1.5:1) and "high ratio" (RBC:FFP > 1.5:1) groups.

185 rival and dichotomized into "low ratio" (RBC:FFP </= 1.5:1) and "high ratio" (RBC:FFP > 1.5:1) groups

186 ed in the massive transfusion protocol's RBC:FFP ratio was associated with a 5.6% reduction in mortal

187 The RBC:FFP ratio decreased from a peak of 1.84:1 in 2007 to 1.5

188 el between those who did and did not receive FFP.

189 The TEG group would receive FFP if the reaction time (r) was >40 min and/or PLT if m

190 Nearly one-half of patients (48.0%) received FFP in the postoperative period with an INR trigger less

191 A total of 44 patients (38.3%) received FFP transfusion.

192 Sixteen SOC (53.3%) received FFP, 10 (33.3%) PLT, and 4 (13.3%) both FFP and PLT.

193 In the TEG group, none received FFP alone (P < 0.0001 vs. SOC), 2 received PLT (6.7%; P

194 All SOC patients received FFP and/or PLT per hospital guidelines.

195 had positive early restaging Ga scans remain FFP (P = .000007).

196 e a product that could supplement or replace FFP.

197 age therapy were most predictive of superior FFP and EFS.

198 test results, and there is no evidence that FFP transfusion alters the risk of bleeding.

199 The FFP:RBC ratio in the OR correlated directly with phase 2

200 The FFP:RBC ratios of survivors and nonsurvivors were nearly

201 erial pH, shock time, RBC, FFP, and BES; the FFP:RBC, BES:RBC, and BES: FFP ratios were given in the

202 concatenated mammalian intronic genomes; the FFP derived intronic genome topologies for each l within

203 We observe that (i) the FFP phylogeny segregates the population into clades, the

204 rus joins the phycodnavirus family; (ii) the FFP tree detects potential evolutionary relationships am

205 13 patients died: eight (35%) of 23 in the FFP group (five from haematoma expansion, all occurring

206 43 serious adverse events (20 in the FFP group and 23 in the PCC group) occurred in 26 patien

207 ic events occurred within 3 days (one in the FFP group and two in the PCC group), and six after day 1

208 Two (9%) of 23 patients in the FFP group versus 18 (67%) of 27 in the PCC group reached

209 lection of feature length is critical in the FFP method, and we have developed a procedure for identi

210 tion of the 3 herpesvirus subfamilies in the FFP tree differs from gene alignment-based analysis; (iv

211 Without this information, the FFP method could only rely on the frequency distribution

212 from gene alignment-based analysis; (iv) the FFP tree suggests the taxonomic positions of certain "un

213 Contrary to recent reports, the FFP:RBC ratio in the OR correlates directly with duratio

214 In the strictest sense, the FFP-based trees are genome phylogenies, not species phyl

215 e show (from the entropy viewpoint) that the FFP procedure could dilute important gene information an

216 Compared to the FFP method, our empirical study showed that the proposed

217 Unlike the FFP method, the TUP method takes the advantage that the

218 certain "unclassified" viruses; and (v) the FFP method identifies candidates for horizontal gene tra

219 5, 54 patients were randomly assigned (26 to FFP and 28 to PCC) and 50 received study drug (23 FFP an

220 Hemostatic transfusion ratios of RBC to FFP approaching 1:1 are associated with a survival advan

221 rrhage, four-factor PCC might be superior to FFP with respect to normalising the INR, and faster INR

222 Outcomes with PCC versus FFP were similar (HR = 1.075, 95% CI = 0.874-1.323, p =

223 The primary end point was FFP: PSA failure (American Society for Therapeutic Radio

224 st common currently used regimen of 3-weekly FFP proved insufficient for 70% of patients and weekly o

225 using standard tree-building algorithms with FFP distances.

226 Nearly one-half of patients transfused with FFP during the postoperative period had an INR of less t

227 We included 1,547 patients treated with FFP (n = 377, 24%), PCC (n = 585, 38%), both (n = 131, 9

228 FP (P < .001) and OS (P < .001), with 5-year FFP ranging from 62% to 88% and 5-year OS ranging from 6

229 ed a narrower range of outcomes, with 5-year FFP ranging from 70% to 88% and 5-year OS ranging from 7

230 a median follow-up of 5.4 years, the 5-year FFP was 89% and the OS was 96%.

231 The 5-year FFP-ASTRO was 85.6% (95% CI, 81.4 to 89.7) with COMBO co

232 The 5-year FFP-Phoenix was 88.0% (95% CI, 84.2 to 91.9) with COMBO

233 Five-year FFP and OS were 78% and 90%, respectively.